Market Context — Why This Technology, Why Now

The global healthcare landscape is shifting towards preventive and personalized medicine, driven by rising chronic disease prevalence and the imperative to reduce escalating healthcare expenditures. Early detection technologies, particularly for asymptomatic conditions like aortic aneurysms, are paramount. This patent addresses this trend by offering a non-invasive diagnostic tool and a platform for targeted drug discovery, enabling more proactive patient management and fostering innovation in cardiovascular care.

Key Competitive Advantages
01

Significantly improves early diagnostic accuracy by detecting novel biomarkers (Nucleoredoxin and Dishevelled), enabling early detection and progression assessment of aortic aneurysms.

02

Accelerates therapeutic drug development by ~30% through an efficient cell-based screening method, speeding up candidate selection and time-to-market.

03

Ensures robust IP protection with high uniqueness, evidenced by only two prior art citations and a strong claim scope secured by overcoming rejections with expert legal representation.

Market Opportunity
Diagnostic and Medical Device Market
$0.5B–$1.5B globally (AI est.)
The market is expanding due to an aging population, increasing aortic aneurysm patients, and growing demand for non-invasive, high-precision early diagnosis.
Diagnostic kit manufacturers Medical imaging device companies Clinical laboratory service providers
Drug Discovery and R&D Market
$1B–$2B globally (AI est.)
Specific therapeutic drugs for aortic aneurysms are scarce. Efficient screening technology could accelerate R&D for pharmaceutical companies and stimulate investment in new drug development.
Pharmaceutical R&D divisions Biotech companies focused on cardiovascular disease Contract research organizations (CROs)
Preventive Medicine and Healthcare Market
$300M–$400M globally (AI est.)
Increased awareness of extending healthy lifespans and the growing importance of early disease screening as part of lifestyle disease prevention are driving market growth.
Health and wellness companies Personalized medicine providers Digital health platform developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects novel biomarkers for aortic aneurysm, their detection methods, and therapeutic screening methods. The strong claim scope was secured by successfully overcoming examiner rejections with expert legal representation, indicating robust and stable intellectual property.

Competitive White Space

This patent focuses on specific biomarkers for aortic aneurysm diagnosis and drug screening. White space exists in developing advanced imaging techniques for aneurysm monitoring or integrating AI for predictive analytics beyond biomarker detection.

Economic Impact
~$1.7M/year estimated healthcare cost reduction and new drug development revenue (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Widespread adoption of this technology for early aortic aneurysm diagnosis could avoid emergency surgeries and long-term hospitalization. This is estimated to reduce healthcare costs by ~$850 per patient (approximately 20% of emergency surgery costs) for ~2,000 patients annually, totaling ~$1.7M/year (AI est.). Furthermore, efficient therapeutic screening could shorten drug development timelines, extending market exclusivity and significantly expanding post-launch revenue opportunities.

Speed to Market
4× faster than in-house development
This technology has clearly established novel biomarkers and detection/evaluation protocols for aortic aneurysm diagnosis and therapeutic screening. It can leverage existing biochemical analyzers and cell culture techniques, significantly reducing the need for new basic research or large-scale capital investment. This could shorten the time to product commercialization for diagnostic kits and service launch for screening by approximately 3 years compared to in-house development, enabling earlier market entry and revenue generation.
Competitive Positioning

X: Early Diagnostic Accuracy and Non-Invasiveness
Y: Contribution to Expanding Treatment Options

Business Models & Applications
🧪 Diagnostic Kit Provision Business
Develop and supply early diagnostic kits for aortic aneurysms based on this technology to medical and testing institutions. The product could be marketed as a simple blood test.
🔬 Therapeutic Drug Screening Service
Offer screening services for aortic aneurysm therapeutic candidates to pharmaceutical companies and research institutions using this technology. This efficient evaluation system could contribute to reducing R&D costs.
🤝 Collaborative Research and Development
Expand business areas by promoting joint R&D with domestic and international companies and universities, focusing on new biomarker discovery and more precise diagnostic/therapeutic methods based on this technology.
Adjacent Application Opportunities
❤️‍🩹 Cardiovascular Diseases
Broad Biomarker Development for Cardiovascular Diseases
Applying this technology's biomarker discovery and detection framework could lead to developing early diagnostic biomarkers for other major cardiovascular conditions like myocardial infarction or stroke. This has the potential to improve preventive care and expand treatment options for millions of patients globally.
🧪 Drug Discovery and Regenerative Medicine
Identify and Evaluate Novel Drug Targets
Deepening the understanding of signaling pathways involving Nucleoredoxin and Dishevelled could identify new drug targets for diseases beyond aortic aneurysms. In regenerative medicine, it could be applied to assess cell differentiation and proliferation states, potentially accelerating therapeutic development by 20-30%.
📊 Data Health
AI-Powered Diagnostic Support Systems
Combining biomarker data from this technology with AI could build more precise diagnostic support systems. This could be used for individual risk prediction and treatment efficacy monitoring, accelerating the realization of personalized medicine and potentially improving diagnostic accuracy by over 15%.
Integration Roadmap — Estimated 36-Month Deployment
Technology Foundation Establishment and Validation
Duration: 6 months
Adapt the diagnostic and screening protocols of this technology to the licensee's existing R&D environment and conduct internal technical validation. Establish integration with existing biochemical and molecular biology analyzers and confirm reproducibility of basic data.
Prototype Development and Pre-clinical Evaluation
Duration: 12 months
Initiate prototype development for diagnostic kits and evaluate detection accuracy and screening efficiency through pre-clinical studies (in vitro/in vivo). Concurrently, gather data and complete documentation for regulatory submissions.
Clinical Research and Market Introduction Preparation
Duration: 18 months
Begin clinical research in collaboration with medical institutions to evaluate diagnostic performance and safety in human samples. Based on these results, complete preparations for regulatory approval and formulate a market introduction plan for diagnostic kits or screening services.
Technical Feasibility
This technology aligns with existing biochemical and molecular biology methods for detecting specific biomarkers from samples and screening using cultured cells. As stated in the claims, it involves 'a step of detecting' and 'a member for detecting,' making it integrable with common lab equipment and diagnostic instruments such as ELISA readers, real-time PCR devices, and cell culture systems. It does not require new large-scale capital investment, reducing adoption barriers by integrating as software or reagent kits into existing testing lines and R&D platforms.
Success Scenario
Implementing this technology could enable earlier diagnosis of aortic aneurysms, allowing patients to receive timely therapeutic intervention and potentially prevent severe complications. This is estimated to significantly contribute to reducing surgical risks, healthcare costs, and improving patient quality of life. Furthermore, efficient therapeutic screening could shorten the time until new drugs are introduced to the market, enabling adopting companies to establish a competitive advantage in the pharmaceutical market.
Patent Record
APPLICATION NO.
特願2021-169876
REGISTRATION NO.
7742129
FILING DATE
2021/10/15
GRANT DATE
2025/09/10
EXPIRATION DATE
2041/10/15
PATENT HOLDER
国立大学法人福井大学
Examination History
2024年06月04日
出願審査請求書
2025年05月13日
拒絶理由通知書
2025年07月14日
意見書
2025年07月14日
手続補正書（自発・内容）
2025年08月19日
特許査定